Contribution ID: 4cdd1b9b-b61d-41f8-90f4-aa6a20a93aa5

Date: 11/10/2017 15:41:11

# Public Consultation: Transformation Health and Care in the Digital Single Market

Fields	marked	with '	* are	mandatory	
iicius	manca	VVILII	aic	manuatory	ï

## Introduction

The purpose of this consultation is to define the need and scope of policy measures that will promote digital innovation in improving people's health, and address systemic challenges to health and care systems. Those measures must be aligned with legislation on the protection of personal data, patient rights and electronic identification. The consultation collects views on:

- Cross-border access to and management of personal health data;
- A joint European exploitation of resources (digital infrastructure, data capacity), to accelerate research and to advance prevention, treatment and personalised medicine;
- Measures for widespread uptake of digital innovation, supporting citizen feedback and interaction between patients and health care providers.

The European Commission reserves the right to publish all contributions to the consultation unless non-publication is specifically requested in the general information section of the questionnaire.

The public online consultation will close on the 12th of October 2017.

In case your response includes confidential data please provide a non-confidential version.

## About you

1 You are welcome to answer the questionnaire in any of the <u>24 official languages</u> of the EU. Please let us know in which language you are replying.

English

- \*2 You are replying
  - as an individual in your personal capacity
  - in your professional capacity or on behalf of an organisation

#### \*10 Respondent's first name

Roberta

#### \*11 Respondent's last name

Savli

### \*12 Respondent's professional email address

roberta.savli@efanet.org

#### \*13 Name of the organisation

European Federation of Allergy and Airways Diseases Patients' Associations

#### \*14 Postal address of the organisation

35, rue du Congres B-1000, Bruxelles

#### \*15 Type of organisation

Please select the answer option that fits best.

- Health and care organisation (e.g. hospitals, clinics, social and community care)
- Service provider (e.g. digital health services, data and technology services, insurance providers)
- Private enterprise (other)
- Professional consultancy, law firm, self-employed consultant
- Trade, business or professional association
- Non-governmental organisation, platform or network
- Research and academia
- Churches and religious communities
- Regional or local authority (public or mixed)
- International or national public authority
- Other

## \*24 Is your organisation included in the Transparency Register?

In the interests of transparency, organisations, networks, platforms or self-employed individuals engaged in activities aimed at influencing the EU decision making process are invited to provide the public with relevant information about themselves, by registering in Transparency Register and subscribing to its Code of Conduct.

Please note: If the organisation is not registered, the submission is published separately from the registered organisations (unless the contributors are recognised as representative stakeholders through Treaty provisions, European Social Dialogue, Art. 154-1)

If your organisation is not registered, we	e invite you to register <u>here</u>	, although it is not comp	ulsory to be registered to	reply to this
consultation. Why a transparency regist	ter?			

\ / ·
VAC

O No

Not applicable

### \*25 If so, please indicate your Register ID number.

28473847513-94

### \*26 Country of organisation's headquarters

- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Poland
- Portugal
- Romania
- Slovak Republic
- Slovenia
- Spain
- Sweden
- United Kingdom
- Other

#### \*28 Your contribution,

Note that, whatever option chosen, your answers may be subject to a request for public access to documents under  $\frac{\text{Regulation (EC)}}{\text{N}^{\circ}1049/2001}$ 

- can be published with your organisation's information (I consent the publication of all information in my contribution in whole or in part including the name of my organisation, and I declare that nothing within my response is unlawful or would infringe the rights of any third party in a manner that would prevent publication)
- can be published provided that your organisation remains anonymous (I consent to the publication of any information in my contribution in whole or in part (which may include quotes or opinions I express) provided that it is done anonymously. I declare that nothing within my response is unlawful or would infringe the rights of any third party in a manner that would prevent the publication.)

Respondents should not include personal data in documents submitted in the context of consultation if they opt for anonymous publication.

## Access to and use of personal data concerning health

A major change in the way we receive and provide health and care services is giving citizens the possibility to effectively manage their health data i.e. to grant access to this data to persons or entities of their choice (e.g. doctors, pharmacists, other service providers, family members, insurances) including <u>across borders</u>, in compliance with EU data protection legislation.

29	Regarding the	statement "Citizens	s should be able t	o manage their ow	n health data" do	VOL
~3	i icuai ulliu ille	Statement Onizeri	s si iuulu be able l	o manaue men ow	ili liballii uala . uu	vou

- Strongly agree
- Agree
- Neither agree nor disagree
- Disagree
- Strongly disagree

30 Comments on previous question (e.g. what kind of information, obligatory self-management of data access vs optional, delegated management only to certain persons or organisations – e.g. doctors, pharmacists, other service providers, family members, others):

1000 character(s) maximum

Patients own their data and should be always able to access and manage them. However, when it comes to interpret the data and to take medical decisions, the consultation of doctors should be obligatory.

- 31 Regarding the statement "Sharing of health data could be beneficial to improve treatment, diagnosis and prevention of diseases across the EU", do you...
  - Strongly agree
  - Agree
  - Neither agree nor disagree
  - Disagree
  - Strongly disagree

#### 32 Comments on previous question:

1000 character(s) maximum

It will also help clinical trials with previous results. The reuse of patients data is also important, especially since it is now possible to analyse and manage big data. On the other hand, patients should be provided with clear information on how and for which purposes their health data will be shared and reused.

33 What are the major barriers to electronic *access* to health data?

Risks of privacy breaches
Legal restrictions in Member States
Lack of infrastructure
Cybersecurity risks
Lack of awareness
☐ Lack of interest
Others
35 What are the major barriers to electronic <i>sharing</i> of health data?
Heterogeneity of electronic health records
Risks of privacy breaches
Legal restrictions in Member States
Lack of infrastructure
☑ Cybersecurity risks
Lack of technical interoperability
Data quality and reliability
Lack of awareness
Lack of interest
☐ Others
37 What should the EU do to overcome barriers to access and sharing of data?
The EU should:
☑ Standardise electronic health records
Propose health-related cybersecurity standards
Support interoperability with open exchange formats
Support health care professionals with common (EU-level) data aggregation
Support patient associations with common (EU-level) data aggregation
Provide the necessary infrastructure for Europe-wide access to health data
Develop standards for data quality and reliability
Increase awareness of rights on data access under European law
Focus on access in cross-border areas
Propose legislation setting the technical standards enabling citizen access and exchange of
Electronic Health Records amongst EU Member States
Other

# Making use of personal data to advance health research, disease prevention, treatment and personalised medicine

The increasing amount of data on the health and lifestyle of individuals has the <u>potential</u> to advance research, improve disease management and support health policy, notably if exploited in a coordinated way across Europe and in compliance with EU data protection legislation.

way across Europe and in compliance with Lo data protection legislation.
39 Would you agree with the principle that personal health data should be made available for further research, on a case-by-case basis, in a secure way, and in compliance with data protection legislation?  Strongly agree  Agree  Neither agree nor disagree  Disagree  Strongly disagree
40 For which purpose would you agree to make your health data available provided this is in compliance with data protection legislation? (Choose as many as you wish)  Improving health care organisation  Improving clinical practice Improving social care organisation  For your own treatment  Progressing research and innovation  Developing health insurance schemes Informing public health programmes  Supporting public health policy making  Helping products development  Increasing efficiency of health and social care  Helping developing countries' health care systems  None of the above  Other
42 If you share your health and/or lifestyle data for research, the following preconditions have to be ensured. (Choose as many as you wish)  Why data is secure and only accessible to authorised parties  My data is encrypted and cannot be traced back to me  My data is only used in 'not for profit' activities  My data is only shared between societies and institutes researching my disease area  Other
44 Should <a href="https://doi.org/10.1001/journal.com/html">https://doi.org/10.1001/journal.com/html</a> , <a href="https://doi.org/10.1001/journal.com/html">big data analytics</a> and <a href="https://doi.org/10.1001/journal.com/html">cloud computing</a> for health research and personalised medicine be advanced?  Yes No

Do not know

500 character(s) maximum	
46 Would it be useful to further develop digital infrastructure to pool health data and reso	ouroop oppurely
across the EU (linking and/or adding to existing infrastructure capacity)?	burces securely
Strongly agree	
O Agree	
Neither agree nor disagree	
Disagree	
Strongly disagree	
47 What, if anything, should the European Commission do to stimulate the use of data a advance research, disease prevention and personalised medicine?  1000 character(s) maximum	and digital tools to
In recent years, many digital tools have been developed with potent impacting in research, prevention and personalised medicine. Howeve application in these sectors is still low and many actions should be form the development of standards for the validity and reliability data processed by apps, to the compatibility of different platforms collection of data, without forgetting the need for raising awarene potential of digital tools for a higher use by patients, researcher healthcare professionals.	er, their te taken, of health for the ess on the
48 Do you / Does your organisation encounter barriers to using big data analytics for pe medicine?	rsonalised
Yes	
O No	
Do not know	
Promoting uptake of digital innovation to support interacti	on between
citizens and health care providers	
<u> </u>	
This section looks at the current status of digital services in health and care. It also addr	esses the role
that individual citizens, health and care providers, industry, public policy authorities and	

50 Do you currently have access to digital health services (e.g. remote monitoring, consultation with

in the improvement of disease prevention and treatment in Europe.

doctors or any other kind of service provided through digital means)?

YesNo

45 What would be the most important application areas?

reatment through
nt feedback to e health and care
feedback in order c authorities and t practices).
and giving citizens
i i i i

### **Useful links**

Do not know

<u>Digital Single Market Mid-term review (https://ec.europa.eu/digital-single-market/en/content/mid-term-review-digit single-market-dsm-good-moment-take-stock)</u>

Special Eurobarometer 460. "Attitudes towards the impact of digitisation and automation on daily life" (https://ec.europa.eu/digital-single-market/en/news/attitudes-towards-impact-digitisation-and-automation-daily-life)

Health in the Digital Single Market (https://ec.europa.eu/digital-single-market/en/policies/ehealth) eHealth policies (http://ec.europa.eu/health/ehealth/policy\_en)

Communication on effective, accessible and resilient health systems (http://eur-lex.europa.eu/legal-content/EN/ALL/?uri=celex:52014DC0215)

Research and innovation in health (https://ec.europa.eu/research/health/index.cfm)

Roadmap: Communication on Digital transformation of health and care in the context of the DSM (https://ec.eurojeu/info/law/better-regulation/initiatives/ares-2017-3647743\_en)

## Contact

EC-DIGICARE-TASKFORCE@ec.europa.eu